InMed CEO, Eric A. Adams, is asked by Shadd Dales of The Dales Repot whether the cost of rare cannabinoids is scalable enough to entice big consumer product companies.
Read the article and watch the full video at The Dales Report.
InMed CEO, Eric A. Adams, is asked by Shadd Dales of The Dales Repot whether the cost of rare cannabinoids is scalable enough to entice big consumer product companies.
Read the article and watch the full video at The Dales Report.
A peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International
InMed’s CEO, Mr. Eric A. Adams, presents at the Emerging Growth Conference. This virtual presentation was given on March 8th, 2023. In the presentation, Mr.
InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, shares results from early neurodegenerative disease studies demonstrating how specific cannabinoids induced neuroprotective effects and
© Copyright 2023 InMed Pharmaceuticals Inc.
"*" indicates required fields